Goethe University
uni-frankfurt.deTotal trials
97
Active
19
Phase 3
5
Total enrollment
46,736
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 12 of 12 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Psychopharmacological treatment | — | — | — | — | — | 1 | |
| Blinatumomab | — | — | — | — | — | 4 | |
| Imatinib | — | — | — | — | 2 | ||
| Osimertinib | — | — | — | — | — | 1 | |
| Pemetrexed | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| Ponatinib | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| Isatuximab | — | — | — | — | — | 1 |
Next readouts
- 2025-11
- 2026-04-30
- 2026-12-31
- 2028-01
- 2028-02
- 2029-07-01
Top conditions
- Adult Acute Lymphocytic Leukemia7
- Acute Lymphoblastic Leukemia3
- Platelet Function2
- Depression2
- Anxiety Disorder2
- Sepsis2
- Mental Disorders2
- Subarachnoid Hemorrhage2
Frequently asked questions about Goethe University
- How many clinical trials does Goethe University have on ClinicalTrials.gov?
- Goethe University is listed as the lead sponsor on 97 clinical trials in ClinicalTrials.gov, 19 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Goethe University's trials are in Phase 3?
- 5 of Goethe University's trials are in Phase 3, spread across 12 active drug programs.
- What therapeutic areas does Goethe University focus on?
- Goethe University's most-studied conditions on ClinicalTrials.gov are Adult Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Platelet Function, Depression, Anxiety Disorder.
- When are Goethe University's next clinical trial readouts?
- Goethe University has 6 upcoming primary-completion readouts tracked here; the soonest is “Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)”, expected around 2025-11.